BridgeBio Pharma (BBIO) is back in focus after the FDA accepted its New Drug Application for encaleret in autosomal dominant hypocalcemia type 1, following positive Phase 3 CALIBRATE data and active launch preparations.

BridgeBio Pharma’s regulatory progress on encaleret comes alongside share price moves that have cooled in the very short term but remain strong over longer horizons, with a 30 day share price return of 10.28% and a 1 year total shareholder return of 73.77%.

If this kind of clinical and regulatory momentum has your attention, it could be a good moment to see what else is happening across healthcare focused AI stocks using the 41 healthcare AI stocks.

BridgeBio Pharma now has an accepted NDA for encaleret, a packed rare disease pipeline, and a share price that has surged over the past year. The next step is simple: Are investors paying a fair price for that position today?

Most Popular Narrative: 229% Overvalued

BridgeBio Pharma closed at $82.14, while the most followed narrative on Simply Wall St places its fair value at $25. That gap is wide enough to make investors ask what is driving the difference.

The "BridgeBio Commercial Bonanza" is priced for perfection, treating the upcoming Acoramidis launch as an automatic cash cow while ignoring a brutal multi-front commercial dogfight.

Want to see why this fair value comes in so far below today's share price? The narrative leans on specific assumptions for revenue ramps, future margins and the profit multiple that would justify them. The full story is in how those inputs fit together.

Result: Fair Value of $25 (OVERVALUED)

However, if BridgeBio Pharma executes more efficiently on launches or if competitor therapies underperform expectations, that could challenge this bearish fair value story.

Another View on BridgeBio Pharma’s Valuation

The user generated narrative pegs BridgeBio Pharma’s fair value at $25, which implies the stock is 229% above that estimate. Our DCF model points in a very different direction. It suggests a future cash flow value of $320.71 per share, with the current $82.14 price trading 74.4% below that figure. Which story do you think fits the risk and reward profile better?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out BridgeBio Pharma for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 56 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

If the mix of optimism and caution around BridgeBio Pharma feels familiar, this is a good time to look at the numbers yourself and move quickly to refine your stance. To see how the current case for BridgeBio balances potential upsides against concerns that investors have already flagged, take a closer look at the 2 key rewards and 1 important warning sign.

Looking for more investment ideas beyond BridgeBio Pharma?

BridgeBio Pharma might already be on your radar, but you do not want to miss other stocks that fit different risk, income, and value profiles using the Simply Wall St screener.

• Target potential mispriced opportunities by scanning for companies flagged in the 56 high quality undervalued stocks.
• Build confidence in capital preservation by focusing on companies highlighted in the 89 resilient stocks with low risk scores.
• Hunt for future standouts by reviewing the screener containing 20 high quality undiscovered gems before the crowd pays attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.